Drug Testing Consent Form

A Drug Testing Consent Form in the United States grants documented consent to the action it describes, on the conditions it states.

For non-DOT private sector employers, there is no single federal statute mandating a specific consent form, but the Drug-Free Workplace Act of 1988 (41 U.S.C. § 701 et seq.) requires federal contractors and grantees to maintain a drug-free workplace policy — and a written consent process is a critical element of a legally defensible policy. The Americans with Disabilities Act (ADA), 42 U.S.C. § 12101 et seq., and the ADA Amendments Act of 2008 (ADAAA) impose constraints on drug testing programs by requiring employers to engage in an interactive process with employees who have disability-related conditions that may affect test results or who are in substance abuse recovery programs.

State law significantly shapes the permissible scope of workplace drug testing. California AB 2188 (effective January 1, 2024, codified at Cal. Gov. Code § 12954) prohibits employers from discriminating against job applicants or employees based on off-duty cannabis use or non-psychoactive cannabis metabolite test results. New York Labor Law § 201-d and the Cannabis Law § 24 restrict adverse employment action based on lawful off-duty activities including cannabis use. Minnesota, New Jersey, and Montana have enacted similar protections. By contrast, states such as Texas, Florida, and Georgia impose few restrictions on employer drug testing programs.

The consent form serves dual purposes: it provides written documentation of the employee's authorization for the employer to conduct the test, share results with the Medical Review Officer (MRO), and take employment action based on results; and it provides the employee with written disclosure of their rights, the consequences of a positive result or refusal to test, and the accommodation process available under the ADA and state law.

A Drug Testing Consent Form is needed whenever an employer administers a drug or alcohol screening to a current employee or job applicant, regardless of whether the test is DOT-regulated or non-regulated.

Pre-employment screening requires a signed consent form before the employer can require an applicant to submit to a drug test as a condition of a conditional offer of employment. In California (Gov. Code § 12954), pre-employment cannabis tests are generally prohibited, but tests for other substances with a signed consent form remain permissible for most positions.

DOT-regulated employers in trucking (FMCSA), aviation (FAA), mass transit (FTA), railroads (FRA), pipelines (PHMSA), and maritime (USCG) must obtain written consent and follow the specific procedures set out in 49 CFR Part 40 for pre-employment, random, post-accident, reasonable suspicion, return-to-duty, and follow-up testing. The Part 40 framework requires use of SAMHSA-certified laboratories, a five-panel test for marijuana (THC metabolites), cocaine, opiates, phencyclidine (PCP), and amphetamines, and a Medical Review Officer (MRO) who must review all non-negative results before reporting to the employer.

Post-accident testing requires a signed consent form (or documented supervisor observation if consent is refused) when an employee is involved in a workplace accident or near-miss that meets the employer's threshold for mandatory testing — for example, any accident involving personal injury or property damage above $1,000 under many company policies, or the more specific criteria under 49 CFR § 382.303 for FMCSA-regulated accidents.

Reasonable suspicion testing requires supervisor documentation of the specific observable signs of drug or alcohol use and a signed consent form before the employee is directed to test. The supervisor documentation and the consent form together protect the employer in any subsequent unemployment or wrongful termination claim.

Return-to-duty testing is required under 49 CFR Part 40 for DOT-regulated employees who tested positive or refused a test, before they are returned to safety-sensitive functions, and a follow-up testing plan of at least six tests in the first twelve months is mandated by the Substance Abuse Professional (SAP) under 49 CFR § 40.307.

A legally adequate Drug Testing Consent Form for US workplace testing must include specific elements to satisfy DOT requirements (for covered employers) and to establish a valid, informed consent for non-DOT employers.

Employee and employer identification: The form must identify the employee or applicant by full legal name, job title or position applied for, date of birth (for MRO chain-of-custody verification), and employee ID or Social Security Number last four digits. The employer's name, address, and DOT registration number (if applicable) must be stated.

Type and reason for testing: The form must specify the category of test being conducted — pre-employment, random (specifying the DOT-regulated pool or non-regulated pool), reasonable suspicion, post-accident, return-to-duty, or follow-up. For DOT-regulated testing, the specific regulatory authority (FMCSA, FAA, FTA, FRA, PHMSA, or USCG) and the Part 40 testing panel (five-panel) must be identified. Non-DOT employers should specify whether the test is a standard five-panel, ten-panel, or expanded panel.

Substances tested and methodology: The form must disclose the specific substances being tested (marijuana/THC metabolites, cocaine, opiates, phencyclidine, amphetamines, and any expanded panel substances) and the testing methodology (urine, oral fluid/saliva, hair follicle, or breath alcohol). For oral fluid testing approved for DOT programs effective June 1, 2023 under the revised 49 CFR Part 40, the form must specify the collection method.

MRO review process: The form must explain that non-negative laboratory results are reviewed by a Medical Review Officer (MRO) — a licensed physician certified by the American Association of Medical Review Officers (AAMRO) or Medical Review Officer Certification Council (MROCC) — before being reported to the employer. The MRO contacts the employee before reporting a verified positive to determine if there is a legitimate medical explanation (valid prescription, medical procedure). The employee's right to contact their MRO and request a split specimen re-test at a second SAMHSA-certified laboratory must be disclosed.

Consequences of positive result or refusal: The form must plainly state the employment consequences of a verified positive result (conditional offer withdrawal, termination, mandatory referral to a Substance Abuse Professional) and the consequences of refusing to test (treated as a positive result under DOT regulations and most non-DOT employer policies; ineligibility for unemployment benefits in most states).

ADA and accommodation rights: The form must include a statement that employees who believe a positive result may be explained by a legitimate medical condition, prescription medication, or disability-related treatment should contact HR or the MRO before the result is finalized. The ADA (42 U.S.C. § 12114(b)) protects individuals in supervised rehabilitation programs who are no longer using illegal drugs.

Medical information confidentiality: The form must state that drug test results are maintained as confidential medical records separate from the general personnel file, consistent with the ADA and applicable state medical privacy laws including California's Confidentiality of Medical Information Act (CMIA), Cal. Civ. Code § 56 et seq.